Vital Signs - Genomics Technology Integration in Proteomics Analysis


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on February 4, 2008, provides an strategic overview of the integration of genomics technology in proteomics analysis. Additionally, a company spotlight is provided for MSM Protein Technologies, an emerging biotechnology company with a suite of tools for drug discovery of functional antibodies and proteins against multi-spanning membrane proteins. Reimbursement and regulatory news from the FDA is also provided for the week of January 21 - January 25, 2008.

Table of Contents

Vital Signs - Genomics Technology Integration in Proteomics AnalysisVital Signs: 4 February 2008This week's issue:




Related Research

Release Date : 09-Jan-18

Region : North America

Release Date : 03-Jan-18

Region : North America

Release Date : 29-Dec-17

Region : North America

Release Date : 28-Dec-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.